Gary Koe Electra Therapeutics

Gary Koe serves as Chief Technical Officer at Electra Therapeutics, bringing more than 30 years of expertise in biopharmaceutical development, large-scale biologics manufacturing, and quality operations. Throughout his career, he has played a pivotal role in advancing complex biologics programs through the various phases of clinical development.

Before joining Electra Therapeutics, Gary was Head of Technical Operations at Aravive, Inc., where he led the large-scale manufacturing of a novel affinity Fc-sAXL fusion protein. His prior experience includes leadership roles of increasing responsibility at prominent biopharmaceutical companies such as Genentech, Valentis, Revance, and Versartis. Gary has overseen the scale-up, technology transfer, manufacturing, and quality control testing for numerous clinical-stage biologics and has managed operations across more than ten manufacturing facilities, including both in-house and contract development and manufacturing organizations (CDMOs).

Gary holds a PhD in Chemical Engineering from the University of California, Los Angeles, and a BS in Chemical Engineering from the University of California, Davis.